Lexeo Therapeutics Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.